An Open-Label Extension Study of GA-GCB ERT in Patients With Type 1 Gaucher Disease

PHASE3CompletedINTERVENTIONAL
Enrollment

95

Participants

Timeline

Start Date

March 13, 2008

Primary Completion Date

December 28, 2012

Study Completion Date

December 28, 2012

Conditions
Gaucher Disease, Type 1
Interventions
BIOLOGICAL

VPRIV®

Intravenous infusion, every other week (EOW)

Trial Locations (21)

10016

NYU Medical Center, New York

30322

Emory University School of Medicine, Atlanta

45229

Cincinnati Children's Hospital Medical Center, Cincinnati

50008

Hospital Universitario Miguel Servet, Zaragoza

53226

Children's Hospital of Wisconsin, Milwaukee

55404

Children's Hospitals and Clinics of Minnesota, Minneapolis

60614

Children's Memorial Hospital, Chicago

64108

Children's Mercy Hospitals & Clinics, Kansas City

84132

University of Utah Medical Center, Salt Lake City

90027

Los Angeles Medical Center, Los Angeles

91031

Shaare Zedek Medical Center, Jerusalem

94609

Children's Hospital Oakland, Oakland

125167

"State Institution Hematology Research Centre RAMS", Moscow

Unknown

Your Health S.A., Buenos Aires

Sociedad Espanola de Socorros Mutuos, Asunción

"Instytut Pomnik-Centrum Zdrowia Dziecka", Warsaw

110 029

All India Institute of Medical Sciences, New Delhi

411 011

KEM Hospital, Pune

660-702

Gyeongsang National University Hospital, Jinju

1007 BS

Hospital de La Rabta, Tunis

NM3 2QG

Royal Free Hospital, London

Sponsors

Lead Sponsor

All Listed Sponsors
lead

Shire

INDUSTRY

NCT00635427 - An Open-Label Extension Study of GA-GCB ERT in Patients With Type 1 Gaucher Disease | Biotech Hunter | Biotech Hunter